Linked Life Data

18092115

Source:http://linkedlifedata.com/resource/pubmed/id/18092115

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2007-12-19
pubmed:abstractText
Considerable controversy exists regarding the cardiovascular safety of COX-2 inhibitors, both in patients with and without established cardiovascular disease. Currently, the major focus is on thrombotic complications presenting as myocardial infarction. I n this report, we present a case of takotsubo cardiomyopathy, also known as the apical ballooning syndrome, precipitated by the use of lumiracoxib. We are concerned that this might be the first case of COX-2 inhibitor-induced apical ballooning syndrome and that more may follow.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1995-1892
pubmed:author
pubmed:issnType
Print
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
383-4
pubmed:dateRevised
2009-11-6
pubmed:meshHeading
pubmed:articleTitle
A case of takotsubo cardiomyopathy precipitated by lumiracoxib, a selective COX-2 inhibitor.
pubmed:affiliation
Department of Physiology, University of Pretoria and Pretoria Heart Hospital, Pretoria.
pubmed:publicationType
Journal Article, Case Reports